Logo for VYNE Therapeutics Inc

VYNE Therapeutics Investor Relations Material

Latest events

Logo for VYNE Therapeutics Inc

R&D Day 2023

VYNE Therapeutics
Logo for VYNE Therapeutics

Q4 2023

29 Feb, 2024
Logo for VYNE Therapeutics

Q3 2023

13 Nov, 2023
Access the full event backlog
Slides, Transcripts, and Reports from 9,000+ public companies

Latest reports from VYNE Therapeutics Inc

Access all reports
VYNE Therapeutics Inc. is a clinical-stage biopharmaceutical company dedicated to developing proprietary therapeutics for the treatment of immuno-inflammatory conditions. The company's product pipeline includes VYN201, a locally administered pan-BET inhibitor designed to address diseases involving multiple inflammatory cell signaling pathways with minimal systemic exposure. Additionally, VYNE is working on VYN202, a BD2-selective oral small molecule, and FMX114, a combination gel in clinical trials for atopic dermatitis. The company is headquartered in Bridgewater, New Jersey, and its shares are listed on the NASDAQ.